Effect of SARS-CoV-2 infection on HBV-infected patients: Reactivation
Background: Hepatic manifestations of COVID-19 are prevalent in individuals infected with viral hepatitis type B (HBV). Objectives: The current study aims to determine the extent of the HBV reactivation depending on the immune impact on patients infected with SARS-CoV-2. Materials and Methods: One h...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2022-01-01
|
| Series: | Medical Journal of Babylon |
| Subjects: | |
| Online Access: | http://www.medjbabylon.org/article.asp?issn=1812-156X;year=2022;volume=19;issue=4;spage=736;epage=746;aulast=Al-Kaif |
| _version_ | 1828011989371191296 |
|---|---|
| author | Laith A I K Al-Kaif Mohammad Abd-Kadhum Al-Saadi Alaa H Al-Charrakh |
| author_facet | Laith A I K Al-Kaif Mohammad Abd-Kadhum Al-Saadi Alaa H Al-Charrakh |
| author_sort | Laith A I K Al-Kaif |
| collection | DOAJ |
| description | Background: Hepatic manifestations of COVID-19 are prevalent in individuals infected with viral hepatitis type B (HBV). Objectives: The current study aims to determine the extent of the HBV reactivation depending on the immune impact on patients infected with SARS-CoV-2. Materials and Methods: One hundred forty-one hospitalized cases were divided into patients infected with HBV with/without SARS-CoV-2 diagnosed by automatic fluorescent immunoassay system COVID-19 Ab (IgM/IgG). Next, HBV reactivation was assessed using hepatitis B surface antigen (HBsAg), HBcAb (IgM), HBeAg, and HBeAb ELISA test. Results: The results showed significant differences in HBV reactivation patients with SARS-CoV-2 at P < 0.05. Out of 141 HBV patients, 115 (1, 80, and 34) had positive COVID-19 in IgM, IgG, and IgM with IgG, respectively. The results of reactivation test showed 34.07% of patients have HBV reactivation. Conclusions: The HBV reactivation patients had been recorded in acute and chronic cases of HBV patients, where no severe cases were recorded compared with the advanced cases of the disease who received immunosuppressive therapy and biological treatment. Therefore, it is necessary to consider the special care of persons exposed to infection with SARS-CoV-2 to patients infected with viral hepatitis, in particular, advanced cases of the disease and their stages of treatment as it leads to liver dysfunction and life-threatening complications. |
| first_indexed | 2024-04-10T09:24:36Z |
| format | Article |
| id | doaj.art-a327648c9c464ee8bfdc5bc890f6094c |
| institution | Directory Open Access Journal |
| issn | 1812-156X 2312-6760 |
| language | English |
| last_indexed | 2024-04-10T09:24:36Z |
| publishDate | 2022-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Medical Journal of Babylon |
| spelling | doaj.art-a327648c9c464ee8bfdc5bc890f6094c2023-02-20T07:22:51ZengWolters Kluwer Medknow PublicationsMedical Journal of Babylon1812-156X2312-67602022-01-0119473674610.4103/MJBL.MJBL_248_22Effect of SARS-CoV-2 infection on HBV-infected patients: ReactivationLaith A I K Al-KaifMohammad Abd-Kadhum Al-SaadiAlaa H Al-CharrakhBackground: Hepatic manifestations of COVID-19 are prevalent in individuals infected with viral hepatitis type B (HBV). Objectives: The current study aims to determine the extent of the HBV reactivation depending on the immune impact on patients infected with SARS-CoV-2. Materials and Methods: One hundred forty-one hospitalized cases were divided into patients infected with HBV with/without SARS-CoV-2 diagnosed by automatic fluorescent immunoassay system COVID-19 Ab (IgM/IgG). Next, HBV reactivation was assessed using hepatitis B surface antigen (HBsAg), HBcAb (IgM), HBeAg, and HBeAb ELISA test. Results: The results showed significant differences in HBV reactivation patients with SARS-CoV-2 at P < 0.05. Out of 141 HBV patients, 115 (1, 80, and 34) had positive COVID-19 in IgM, IgG, and IgM with IgG, respectively. The results of reactivation test showed 34.07% of patients have HBV reactivation. Conclusions: The HBV reactivation patients had been recorded in acute and chronic cases of HBV patients, where no severe cases were recorded compared with the advanced cases of the disease who received immunosuppressive therapy and biological treatment. Therefore, it is necessary to consider the special care of persons exposed to infection with SARS-CoV-2 to patients infected with viral hepatitis, in particular, advanced cases of the disease and their stages of treatment as it leads to liver dysfunction and life-threatening complications.http://www.medjbabylon.org/article.asp?issn=1812-156X;year=2022;volume=19;issue=4;spage=736;epage=746;aulast=Al-Kaifcoinfectionhbvhbv reactivationsars-cov-2 |
| spellingShingle | Laith A I K Al-Kaif Mohammad Abd-Kadhum Al-Saadi Alaa H Al-Charrakh Effect of SARS-CoV-2 infection on HBV-infected patients: Reactivation Medical Journal of Babylon coinfection hbv hbv reactivation sars-cov-2 |
| title | Effect of SARS-CoV-2 infection on HBV-infected patients: Reactivation |
| title_full | Effect of SARS-CoV-2 infection on HBV-infected patients: Reactivation |
| title_fullStr | Effect of SARS-CoV-2 infection on HBV-infected patients: Reactivation |
| title_full_unstemmed | Effect of SARS-CoV-2 infection on HBV-infected patients: Reactivation |
| title_short | Effect of SARS-CoV-2 infection on HBV-infected patients: Reactivation |
| title_sort | effect of sars cov 2 infection on hbv infected patients reactivation |
| topic | coinfection hbv hbv reactivation sars-cov-2 |
| url | http://www.medjbabylon.org/article.asp?issn=1812-156X;year=2022;volume=19;issue=4;spage=736;epage=746;aulast=Al-Kaif |
| work_keys_str_mv | AT laithaikalkaif effectofsarscov2infectiononhbvinfectedpatientsreactivation AT mohammadabdkadhumalsaadi effectofsarscov2infectiononhbvinfectedpatientsreactivation AT alaahalcharrakh effectofsarscov2infectiononhbvinfectedpatientsreactivation |